PMID- 9743519
OWN - NLM
STAT- MEDLINE
DCOM- 19981015
LR  - 20190508
IS  - 0022-1007 (Print)
IS  - 1540-9538 (Electronic)
IS  - 0022-1007 (Linking)
VI  - 188
IP  - 6
DP  - 1998 Sep 21
TI  - Translation of a retained intron in tyrosinase-related protein (TRP) 2 mRNA 
      generates a new cytotoxic T lymphocyte (CTL)-defined and shared human melanoma 
      antigen not expressed in normal cells of the melanocytic lineage.
PG  - 1005-16
AB  - We report here the identification of a new shared human melanoma antigen 
      recognized by a human leukocyte antigen (HLA)-A*68011-restricted cytotoxic T 
      lymphocyte clone (CTL 128). The cDNA encoding this antigen is composed of a 
      partially spliced form of the melanocyte differentiation antigen 
      tyrosinase-related protein (TRP)-2, containing exons 1-4 with retention of intron 
      2 and part of intron 4 (TRP-2-INT2). The sequence coding for the antigenic 
      epitope is located at the 5' end of intron 2 and is available for translation in 
      the same open reading frame of the fully spliced TRP-2 mRNA. This peptide is also 
      recognized by CTL 128 when presented by the HLA-A*3301, a member of the 
      HLA-A3-like supertype that includes the HLA-A*68011. Quantitative reverse 
      transcription PCR analysis carried out on total and/or cytoplasmic mRNA 
      demonstrated that, in contrast to the fully spliced TRP-2 mRNA expressed in 
      melanomas, normal skin melanocytes, and retina, the TRP-2-INT2 mRNA could be 
      detected at significant levels in melanomas but not in normal cells of the 
      melanocytic lineage. Instead, in these normal samples, both the spliced and the 
      unspliced transcript of gp100 were expressed at high levels. Absence of 
      endogenous TRP-2-INT2 expression in melanocytes was also confirmed by lack of 
      recognition of HLA-A*68011-transduced, TRP-2(+) melanocyte lines by CTL 128. 
      These results indicate that a partially spliced form of a differentiation antigen 
      mRNA, present in the cytoplasmic compartment of neoplastic but not normal cells 
      of the melanocytic lineage, can be the source of a melanoma-restricted T cell 
      epitope.
FAU - Lupetti, R
AU  - Lupetti R
AD  - Division of Experimental Oncology D, Istituto Nazionale Tumori, Milan, Italy.
FAU - Pisarra, P
AU  - Pisarra P
FAU - Verrecchia, A
AU  - Verrecchia A
FAU - Farina, C
AU  - Farina C
FAU - Nicolini, G
AU  - Nicolini G
FAU - Anichini, A
AU  - Anichini A
FAU - Bordignon, C
AU  - Bordignon C
FAU - Sensi, M
AU  - Sensi M
FAU - Parmiani, G
AU  - Parmiani G
FAU - Traversari, C
AU  - Traversari C
LA  - eng
SI  - GENBANK/AJ000503
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Exp Med
JT  - The Journal of experimental medicine
JID - 2985109R
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (DNA, Complementary)
RN  - 0 (Epitopes)
RN  - 0 (HLA-A3 Antigen)
RN  - 0 (Peptides)
RN  - 0 (RNA, Messenger)
RN  - EC 5.3.- (Intramolecular Oxidoreductases)
RN  - EC 5.3.3.12 (dopachrome isomerase)
SB  - IM
MH  - Alleles
MH  - Animals
MH  - Antigen Presentation/genetics
MH  - Antigens, Neoplasm/*biosynthesis/genetics/immunology
MH  - Base Sequence
MH  - COS Cells
MH  - Cloning, Molecular
MH  - DNA, Complementary/isolation & purification
MH  - Epitopes/biosynthesis/immunology
MH  - Gene Expression Regulation, Neoplastic/immunology
MH  - HLA-A3 Antigen/genetics
MH  - Histocompatibility Testing
MH  - Humans
MH  - Intramolecular Oxidoreductases/*genetics
MH  - *Introns
MH  - Melanocytes/*immunology/metabolism
MH  - Melanoma/genetics/*immunology
MH  - Molecular Sequence Data
MH  - Peptides/genetics/immunology/metabolism
MH  - Polymerase Chain Reaction
MH  - *Protein Biosynthesis
MH  - RNA, Messenger/*genetics
MH  - T-Lymphocytes, Cytotoxic/*immunology
MH  - Tumor Cells, Cultured
PMC - PMC2212536
EDAT- 1998/09/22 00:00
MHDA- 1998/09/22 00:01
PMCR- 1999/03/21
CRDT- 1998/09/22 00:00
PHST- 1998/09/22 00:00 [pubmed]
PHST- 1998/09/22 00:01 [medline]
PHST- 1998/09/22 00:00 [entrez]
PHST- 1999/03/21 00:00 [pmc-release]
AID - 10.1084/jem.188.6.1005 [doi]
PST - ppublish
SO  - J Exp Med. 1998 Sep 21;188(6):1005-16. doi: 10.1084/jem.188.6.1005.